Advertisement

Foam Cell-Derived CXCL14 Muti-Functionally Promotes Atherogenesis and Is a Potent Therapeutic Target in Atherosclerosis

  • Weilin Tong
  • Yaqi Duan
  • Rumeng Yang
  • Ying Wang
  • Changqing Peng
  • Zitian HuoEmail author
  • Guoping WangEmail author
Original Article
  • 53 Downloads

Abstract

CXC chemokine family has been related to atherogenesis for long. However, the relationship between CXCL14 and atherogenesis is still unclear. This study preliminarily detected CXCL14 expression at foam cells in atherosclerosis specimens by immunohistochemistry. In vitro foam cells were derived from THP-1 after phorbol-12-myristate-13-acetate (PMA) and oxidized low-density lipoprotein (ox-LDL) stimulation. Immunoblotting and qPCR convinced CXCL14 expression variation during foam cell formation. We further demonstrated that ox-LDL regulated CXCL14 expression by AP-1. AP-1 could bind to CXCL14 promoter and up-regulate CXCL14 mRNA expression. Besides, CXCL14 promoted THP-1 migration, macrophage lipid phagocytosis, and smooth muscle cell migration as well as proliferation mainly via the ERK1/2 pathway. Additionally, a CXCL14 peptide-induced immune therapy showed efficacy in ApoE−/− mouse model. In conclusion, our study demonstrated that CXCL14 is highly up-regulated during foam cell formation and promotes atherogenesis in various ways. CXCL14 may be a potent therapeutic target for atherosclerosis.

Keywords

Foam cell Atherogenesis CXCL14 

Notes

Author Contributions

W.T., R.Y., C.P., and Y.W. conducted the experiments. Y.D. analyzed the results. W.T. wrote the manuscript. Z.H. and G.W. conceived the experiments. All authors reviewed the manuscript.

Funding Information

This study was supported in part by research grants 81770263, 81570254, and 31271040 from the National Natural Science Foundation of China.

Compliance with Ethical Standards

All experimental protocols were approved by the Ethical Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. All animal studies were performed in accordance with the Guidelines of the Hubei Council of Animal Care and approved by the Experimental Animal Committee of the Huazhong University of Science and Technology in China. The informed consent was obtained from all subjects, and this study is approved by the Ethical Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.

Competing Interests

The authors declare that they have no competing interests.

Supplementary material

12265_2019_9915_MOESM1_ESM.jpg (75 kb)
ESM 1 (JPG 74 kb)
12265_2019_9915_MOESM2_ESM.jpg (197 kb)
ESM 2 (JPG 196 kb)
12265_2019_9915_MOESM3_ESM.jpg (108 kb)
ESM 3 (JPG 107 kb)

References

  1. 1.
    Ference, B. A., Ginsberg, H. N., Graham, I., et al. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.[J]. European Heart Journal, 38, 2459–2472.CrossRefGoogle Scholar
  2. 2.
    Cao Dian, J. (2018). Macrophages in cardiovascular homeostasis and disease.[J]. Circulation, 138, 2452–2455.CrossRefGoogle Scholar
  3. 3.
    Tabas, I., & Lichtman, A. H. (2017). Monocyte-macrophages and T cells in atherosclerosis.[J]. Immunity, 47, 621–634.CrossRefGoogle Scholar
  4. 4.
    Puca, A. A., Carrizzo, A., Spinelli, C., et al. (2019). Single systemic transfer of a human gene associated with exceptional longevity halts the progression of atherosclerosis and inflammation in ApoE knockout mice through a CXCR4-mediated mechanism.[J]. European Heart Journal published ahead of time.Google Scholar
  5. 5.
    Li, X., Kemmer, L., Zhang, X., et al. (2018). Anti-inflammatory effects on atherosclerotic lesions induced by CXCR4-directed endoradiotherapy.[J]. Journal of the American College of Cardiology, 72, 122–123.CrossRefGoogle Scholar
  6. 6.
    Sainz, J., & Sata, M. (2007). CXCR4, a key modulator of vascular progenitor cells.[J]. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 263–265.CrossRefGoogle Scholar
  7. 7.
    Merckelbach, S., van der Vorst, E. P. C., Kallmayer, M., et al. (2018). Expression and cellular localization of CXCR4 and CXCL12 in human carotid atherosclerotic plaques.[J]. Thrombosis and Haemostasis, 118, 195–206.CrossRefGoogle Scholar
  8. 8.
    Salogni, L., Musso, T., Bosisio, D., et al. Activin A induces dendritic cell migration through the polarized release of CXC chemokine ligands 12 and 14. Blood, 113(23), 5848–5856.CrossRefGoogle Scholar
  9. 9.
    Lu, J., Chatterjee, M., Schmid, H., et al. CXCL14 as an emerging immune and inflammatory modulator. Journal of Inflammation (Lond)., 13, 1.Google Scholar
  10. 10.
    Sleeman, M. A., Fraser, J. K., Murison, J. G., Kelly, S. L., et al. B cell- and monocyte-activating chemokine (BMAC), a novel non-ELR alphachemokine. International Immunology, 12(5), 677–689.Google Scholar
  11. 11.
    Frederick, M. J., Henderson, Y., et al. In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. The American Journal of Pathology, 156(6), 1937–1950.CrossRefGoogle Scholar
  12. 12.
    Kurth, I., Willimann, K., Schaerli, P., et al. Monocyte selectivity and tissue localization suggests a role for breast and kidney-expressed chemokine (BRAK) in macrophage development. The Journal of Experimental Medicine, 194(6), 855–861.CrossRefGoogle Scholar
  13. 13.
    Ozawa, S., Kato, Y., Komori, R., et al. BRAK/CXCL14 expression suppresses tumor growth in vivo in human oral carcinoma cells. Biochemical and Biophysical Research Communications, 348(2), 406–412.CrossRefGoogle Scholar
  14. 14.
    Tessema, M., Klinge, D. M., Yingling, C. M., et al. Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis. Oncogene., 29(37), 5159–5170.CrossRefGoogle Scholar
  15. 15.
    Song, E. Y., Shurin, M. R., Tourkova, I. L., et al. Epigenetic mechanisms of promigratory chemokine CXCL14 regulation in human prostate cancer cells. Cancer Research, 70(11), 4394–4401.CrossRefGoogle Scholar
  16. 16.
    Nara, N., Nakayama, Y., Okamoto, S., et al. (2007). Disruption of CXC motif chemokine ligand-14 in mice ameliorates obesity-induced insulin resistance.[J]. The Journal of Biological Chemistry, 282, 30794–30803.CrossRefGoogle Scholar
  17. 17.
    Tanegashima, K., Suzuki, K., Nakayama, Y., et al. (2010). Antibody-assisted enhancement of biological activities of CXCL14 in human monocytic leukemia-derived THP-1 cells and high fat diet-induced obese mice.[J]. Experimental Cell Research, 316, 1263–1270.CrossRefGoogle Scholar
  18. 18.
    Poon, W.-L., Alenius, H., Ndika, J., et al. (2017). Nano-sized zinc oxide and silver, but not titanium dioxide, induce innate and adaptive immunity and antiviral response in differentiated THP-1 cells.[J]. Nanotoxicology, 11, 936–951.CrossRefGoogle Scholar
  19. 19.
    Pelicano, H., et al. Mitochondrial dysfunction and reactive oxygen species imbalance promote breast cancer cell motility through a CXCL14-mediated mechanism. Cancer Research, 69(6), 2375–2383.CrossRefGoogle Scholar
  20. 20.
    Foncea, R., Mazière, C., et al. Endothelial cell oxidative stress and signal transduction. Biological Research, 33(2), 89–96.Google Scholar
  21. 21.
    Suxia, M., Zhifeng, B., et al. The DPP-4 inhibitor saxagliptin ameliorates ox-LDL-induced endothelial dysfunction by regulating AP-1 and NF-κB. European Journal of Pharmacology, 851, 186–193.Google Scholar
  22. 22.
    Sterner, R. M., Takahashi, P. Y., Yu, B., & Aimee, C. (2016). Active vaccines for Alzheimer disease treatment.[J]. Journal of the American Medical Directors Association, 17, 862.e11–862.e15.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Weilin Tong
    • 1
    • 2
  • Yaqi Duan
    • 1
    • 2
  • Rumeng Yang
    • 1
    • 2
  • Ying Wang
    • 1
    • 2
  • Changqing Peng
    • 1
    • 2
  • Zitian Huo
    • 1
    • 2
    Email author
  • Guoping Wang
    • 1
    • 2
    Email author
  1. 1.Institute of Pathology, Tongji Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanPeople’s Republic of China
  2. 2.Department of Pathology, School of Basic Medicine, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanPeople’s Republic of China

Personalised recommendations